^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TH-1904
i
Other names: TH-1904, TH1904, doxorubicin-TH19P01 conjugate, conjugate of Doxorubicin and TH-19P01, TH 1904
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Theratechnologies
Drug class:
Sortilin inhibitor
Related drugs:
3years
New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells. (PubMed, Front Oncol)
In contrast, VM was unaffected by unconjugated Doxorubicin or Doxil (liposomal Doxorubicin) up to μM concentrations. Overall, current data evidence for the first time that 1) SORT1 itself exerts a crucial role in both ES-2 and MDA-MB-231 VM, and that 2) VM in these cancer cell models can be efficiently inhibited by the peptide-drug conjugates TH1902/TH1904. These new findings also indicate that both peptide-drug conjugates, in addition to their reported cytotoxicity, could possibly inhibit VM in SORT1-positive TNBC and ovarian cancer patients.
Journal
|
SORT1 (Sortilin 1) • CD31 (Platelet and endothelial cell adhesion molecule 1) • MMP9 (Matrix metallopeptidase 9)
|
doxorubicin hydrochloride • pegylated liposomal doxorubicin • sudocetaxel zendusortide (TH 1902) • TH-1904
Share via
